Get started
Author

Mirte van der Heijden

Observed names: M. van der Heijden, Mirte Van der Heijden, van der Heijden, Mirte
ORCID: 0009-0000-4123-6464
Observed ORCID: 0009-0000-4123-6464
OpenAlex ID: A5102737024
The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial
2025 · Matthew Stephen Block, James Hugo Armstrong Clubb, et al. · Nature Communications · 40
PDF
Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024 · Santeri A. Pakola, Katriina J. Peltola, et al. · Clinical Cancer Research · 37
PDF
Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways
2024 · Naziia Kurmasheva, Aida Said, et al. · Nature Communications · 32
Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine
2024 · Saru Basnet, Mirte Van der Heijden, et al. · Molecular Therapy · 23
Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial
2025 · Santeri A Pakola, James H A Clubb, et al. · Journal for ImmunoTherapy of Cancer · 11
PDF
Oncolytic adenovirus encoding variant interleukin-2 combined with chemotherapy enables PD-L1 inhibition in pancreatic cancer models
2025 · Santeri A. Pakola, Nea Ojala, et al. · Cancer Immunology Immunotherapy · 6
PDF
Single-cell profiling of peripheral blood mononuclear cells from patients treated with oncolytic adenovirus TILT-123 reveals baseline immune status as a predictor of therapy outcomes
2025 · Tatiana V. Kudling, Dmitrii Bychkov, et al. · Cancer Gene Therapy · 6
Boosting anti-tumor immunity with TILT-517 oncolytic adenovirus and checkpoint blockade in renal cell carcinoma
2025 · Victor Arias, Tatiana V. Kudling, et al. · Molecular Therapy Oncology · 5
Dyslipidemia-associated natural IgM improves oncolytic virus TILT-123 efficacy through antibody-dependent enhancement in solid tumors
2026 · James Hugo Armstrong Clubb, Santeri Artturi Pakola, et al. · Molecular Therapy · 3
PDF
Fully intravenous split-dose administration of the oncolytic adenovirus TILT-123 in advanced solid tumors
2026 · Elise Jirovec, Katriina J. Jalkanen, et al. · Molecular Therapy · 2
Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine
2024 · Saru Basnet, Mirte Van der Heijden, et al. · Molecular Therapy · 2
PDF
Alistipes and Eggerthella shape the response to oncolytic adenovirus therapy in mice and humans through short-chain fatty acid metabolism
2026 · Mirte van der Heijden, James Hugo Armstrong Clubb, et al. · OncoImmunology · 1
PDF
6P Natural IgM and dyslipidemia enhance the efficacy of tumor necrosis factor and interleukin-2 encoding oncolytic adenovirus in solid tumors
2025 · J.H.A. Clubb, S.A. Pakola, et al. · Immuno-Oncology Technology · 1
Author Correction: Octyl itaconate enhances VSVΔ51 oncolytic virotherapy by multitarget inhibition of antiviral and inflammatory pathways
2024 · Naziia Kurmasheva, Aida Said, et al. · Nature Communications · 1
PDF
Abstract CT139: Immunological activity of oncolytic adenovirus encoding TNFα and IL-2 (TILT-123) in combination with pembrolizumab in platinum resistant or refractory ovarian cancer patients
2024 · James H. Clubb, Matthew S. Block, et al. · Cancer Research · 1
Effects of Concomitant Medications on Clinical and Immunological Outcomes of Cancer Patients Treated With Oncolytic Adenoviruses
2026 · Santeri A. Pakola, Tatiana V. Kudling, et al. · International Journal of Cancer
PDF
Antiviral humoral immunity as biomarker and effector in oncolytic adenovirus TILT-123 therapy
2026 · Victor Arias, James H Clubb, et al. · Journal for ImmunoTherapy of Cancer
PDF
259P Intravenous oncolytic adenovirus encoding tumor necrosis factor and interleukin 2 with immunomodulatory metronomic cyclophosphamide in patients with advanced solid tumors
2025 · S.A. Pakola, K. Jalkanen, et al. · Immuno-Oncology Technology
5P Neutralizing antibodies as functional effectors and predictive biomarkers in oncolytic adenovirus therapy
2025 · V. Arias Illana, J.H.A. Clubb, et al. · Immuno-Oncology Technology
PDF
Assessment of tumors, blood, and ascites to establish correlations with treatment benefit in platinum resistant or refractory ovarian cancer patients treated with igrelimogene litadenorepvec and pembrolizumab combination therapy.
2025 · Victor Cervera, James Clubb, et al. · Journal of Clinical Oncology
Abstract 2035: Clinical-immunological correlates in platinum resistant or refractory ovarian cancer patients treated with chimeric oncolytic adenovirus encoding TNFa and IL-2 (TILT-123) in combination with pembrolizumab
2025 · James H. Clubb, Matthew Block, et al. · Cancer Research
722 Immunoprofiling and correlative analysis from PROTA: a phase I trial combining an oncolytic adenovirus encoding TNFα and IL2 with pembrolizumab for platinum-resistant or refractory ovarian cancer
2024 · James HA Clubb, Joao Santos, et al. · Journal for ImmunoTherapy of Cancer
Figure 2 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024 · Santeri A. Pakola, Katriina J. Peltola, et al.
Supplementary Data 1 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024 · Santeri A. Pakola, Katriina J. Peltola, et al.
Table 1 from Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
2024 · Santeri A. Pakola, Katriina J. Peltola, et al.
Works count: 34
Citation count: 166
H-index: 6
I10-index: 5
Year
Topic
Type